Study Evaluating Sirolimus in Kidney Transplant Recipients

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted patients treated with cyclosporine, mycophenolate and corticosteroids.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Cyclosporine; Cyclosporins; Daclizumab; Everolimus; Immunoglobulin G; Mycophenolate mofetil; Mycophenolic Acid; Sirolimus

Criteria

Inclusion Criteria:

• Kidney transplantation

• Donor must be at least 60 years old.

Exclusion Criteria:

• Current systemic infection

• Unstable angina or treatment for serious arrhythmia.

• Cancer within the previous 5 years.